Safety and Efficacy Study of Artificial Cornea

NCT ID: NCT01018888

Last Updated: 2013-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the stability of artificial cornea manufactured by Aurolab and to assess its visual outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The keratoprosthesis, also know as an artificial cornea plays a significant role in combating corneal blindness in patients who are no longer candidates for penetrating keratoplasty.The global incidence of corneal blindness is estimated to be 6-8 million. In India there are approximately 6.8 million cases of unilateral corneal blindness and 1.3 million people with bilateral corneal pathology.

Eligible subjects after getting informed consent will be included in this study. All the subjects will have pre-operative evaluation which includes history, visual acuity, Intraocular pressure (IOP), evaluation of tear film and ultrasound A and B scan. Ocular inflammation will be controlled prior to surgery. Keratoplasty will be performed with keratoprosthesis under local anesthesia. Patients will be followed up at regular interval to assess the outcome variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corneal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Keratoprosthesis

Group Type EXPERIMENTAL

Auro KPro (Keratoprosthesis)

Intervention Type DEVICE

Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Auro KPro (Keratoprosthesis)

Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Auro KPro

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age more than 20 years
* Willing to participate and review on schedule
* Multiple failed grafts with poor prognosis for regrafting
* Adequate tear film and lid function
* Projection of light in all quadrants
* Bilateral blind

Exclusion Criteria

* Reasonable chance of success with keratoplasty
* Autoimmune disease such as Stevens Johnson Syndrome, Pemphigoid
* End stage glaucoma
* Retinal detachment
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aurolab

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Jeena Mascarenhas, MBBS, MS

Role: PRINCIPAL_INVESTIGATOR

Aravind Eye Hospital, Madurai

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aravind Eye Hospital

Madurai, Tamil Nadu, India

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mr.Karthikumar S, M.Pharm

Role: CONTACT

0452-3096100 ext. 229

Elakiya S, M.Sc

Role: CONTACT

0452-4356100 ext. 364

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mr. Gobinath, B.Pharm

Role: primary

0452-4356100 ext. 364

Muthu Selvi, BA., BBE

Role: backup

0452-4356100 ext. 364

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1PN1010941

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.